FDA Biologics Center Seeking To Address Device Industry Concerns – Zoon
This article was originally published in The Gray Sheet
Executive Summary
Responsibility for the regulation of products related to blood safety should remain with FDA's Center for Biologics Evaluation & Research, according to CBER Director Kathryn Zoon
You may also be interested in...
CBER Should Retain Jurisdiction of Assigned Device Reviews – HHS Report
Improved device review times, including speedy handling of West Nile Virus diagnostics, convinced HHS that the Center for Biologics Evaluation & Research should retain jurisdiction over blood and tissue-related devices already assigned to the center
CBER Should Retain Jurisdiction of Assigned Device Reviews – HHS Report
Improved device review times, including speedy handling of West Nile Virus diagnostics, convinced HHS that the Center for Biologics Evaluation & Research should retain jurisdiction over blood and tissue-related devices already assigned to the center
CBER Deputy Director Goodman To Assume Biologics Directorship In January
Incoming Center for Biologics Evaluation & Research Director Jesse Goodman, MD, brings a working relationship with blood test manufacturers from his experience as CBER deputy director